President and CEOOfficers of the CorporationBoard of TrusteesLeadership CouncilHistory
Managing DiabetesChildhood DiabetesNutritionExerciseOnline Diabetes ClassesDiscussion BoardsInfo for Healthcare ProfessionalsJoslin Clinical Guidelines50-Year Medalist Program
Adult ClinicPediatricsEye CareBillingInfo for Healthcare Professionals
Directory of Joslin InvestigatorsDiabetes Research Center Alumni Connection
Media RelationsNews ReleasesInside JoslinSocial Media
Affiliated CentersPharma & DeviceCorporate EducationPublicationsProfessional EducationInternational
Give NowHow You Can Help JoslinHigh Hopes FundGet InvolvedEventsCorporate & Foundation SupportPlanned GivingPhilanthropy Team

News Release

Joslin Diabetes Center Announces Two New Senior Executives

BOSTON (October 6, 2014) – Joslin Diabetes Center today announced the addition of two new senior executives to its management team: Eliot M. Lurier, Chief Financial Officer, and Alicia Peters-Torrey, Chief Information Officer.

Mr. Lurier comes to Joslin with more than 30 years of experience with life sciences organizations, including corporations involved in pharmaceutical development, wellness and patient care.  He most recently served as Chief Financial Officer and Treasurer at Interleukin Genetics, Inc.  Prior to joining Interleukin Genetics, he was Vice President, Finance and Administration and Chief Financial Officer at NUCRYST Pharmaceuticals.  Mr. Lurier earned a B.S. in Accounting from Syracuse University and is a Certified Public Accountant.

Before joining Joslin, Ms. Peters-Torrey was the Founder and Principal of Adapt Health Information Technology, specializing in deployment and improvement of technology in non-profit health care organizations.  She previously served as Chief Information Officer at the Maine Primary Care Association. Ms. Peters-Torrey is a graduate of the University of Maine.

“Joslin is fortunate to have two such outstanding professionals as Eliot and Alicia overseeing our financial and IT operations,” said Joslin Diabetes Center President and CEO John L. Brooks III.  “I look forward to working with them as we implement our long-range innovation plans. As we continue to work toward a cure for diabetes, we are also working to ensure Joslin care is available to those living with type I and type II diabetes, wherever they need us; the addition of Eliot and Alicia is a great organizational step, in helping us to expand our reach.”

###